Search results for "Drug interactions"

showing 10 items of 229 documents

Atenolol interaction with aspirin, allopurinol, and ampicillin.

1983

Atenolol kinetics were investigated in six healthy subjects after 100 mg orally, as monotherapy a 6-day treatment began 48 hr later. After a therapy-free interval of 4 wk, the same subjects received the same dose of atenolol with 1 gm ampicillin, 500 mg aspirin, and with 300 mg allopurinol. Allopurinol and aspirin did not substantially alter the kinetics of atenolol. After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy. During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01). Mean peak plasma levels were lowered…

AdultMaleCombination therapyUrinary systemAllopurinolPhysical ExertionAllopurinolBiological AvailabilityBlood PressurePharmacologyPropanolaminesHeart RateAmpicillinmedicineHumansPharmacology (medical)Drug Interactionscardiovascular diseasesPharmacologyAspirinAspirinChemistryAtenololBioavailabilityKineticsBlood pressureAtenololAmpicillinFemalecirculatory and respiratory physiologymedicine.drugClinical pharmacology and therapeutics
researchProduct

Pharmacokinetic analysis of the interaction between dicoumarol and tolbutamide in man

1976

The effect of repeated administration of tolbutamide on the elimination and anticoagulant action of a single oral dose of dicoumarol 600 mg was studied in four healthy male subjects using a crossover design. In all subjects the plasma concentration of dicoumarol in the postabsorptive phase was lower during concomitant tolbutamide treatment. However, the subjects differed with respect to the elimination kinetics of dicoumarol and the effect of tolbutamide on some of the measured pharmacokinetic paramaters. In two subjects dicoumarol was eliminated by apparent first-order kinetics. Tolbutamide led to a pronounced increase in the elimination rate and a shift in the plasma concentration-respons…

AdultMaleDicumarolmedicine.medical_specialtymedicine.drug_classTolbutamidePharmacologySingle oral dosechemistry.chemical_compoundTolbutamidePharmacokineticsInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)PharmacologyAnticoagulantGeneral MedicineDicoumarolCoumarinCrossover studyPharmacokinetic analysisEndocrinologychemistryHalf-LifeProtein Bindingmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003

INTRODUCTION Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly a…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyMelperoneVenlafaxine HydrochlorideVenlafaxinePharmacologyMethylationPharmacokineticsOral administrationCytochrome P-450 CYP2D6 InhibitorsInternal medicineDextrorphanmedicineHumansDrug InteractionsPharmacology (medical)AgedRetrospective StudiesChemistryVenlafaxine HydrochlorideGeneral MedicineDextromethorphanMiddle AgedCyclohexanolsButyrophenonesPsychiatry and Mental healthEndocrinologyCytochrome P-450 CYP2D6Drug Therapy CombinationFemaleDrug MonitoringReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Interaction of atenolol with furosemide and calcium and aluminum salts

1981

Six healthy subjects were treated with 100 mg atenolol. After a therapy-free interval of 4 wk the same subjects received the same dose of atenolol with furosemide, 40 mg, with calcium (as the lactate gluconate and carbonate), 500 mg, or with aluminum hydroxide, 5.6 gm. Atenolol alone and in combination was administered first as a single oral dose; a long-term 6-day treatment began 48 hr later. Addition of furosemide did not influence atenolol kinetics, but aluminum hydroxide led to an insignificant reduction (P greater than 0.05) of mean peak plasma levels of about 20% and of the area under the plasma concentration-time curve (AUC -infinity) from 5818 to 4353 ng ml-1 hr (P greater than 0.05…

AdultMaleTachycardiamedicine.medical_specialtyPhysical Exertionchemistry.chemical_elementBlood PressureCalciumPharmacologyPropanolaminesFurosemideHeart RateInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)PharmacologyHealthy subjectsFurosemideAluminum saltsMiddle AgedAtenololKineticsPeak plasmaEndocrinologyBlood pressureAtenololchemistryHypertensionCalciumFemalemedicine.symptomAluminumcirculatory and respiratory physiologymedicine.drugClinical Pharmacology and Therapeutics
researchProduct

Contractile responses of human thyroid arteries to vasopressin

2013

Abstract Aims In the present study we investigated the intervention of nitric oxide and prostacyclin in the responses to vasopressin of isolated thyroid arteries obtained from multi-organ donors. Main methods Paired artery rings from glandular branches of the superior thyroid artery, one normal and the other deendothelised, were mounted in organ baths for isometric recording of tension. Concentration–response curves to vasopressin were determined in the absence and in the presence of either the vasopressin V 1 receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 − 8  M), the nitric oxide synthase inhibitor N G -monomethyl- l -arginine ( L -NMMA, 10 − 4  M), or the inhibitor of prostaglandins indom…

AdultMaleVasopressinmedicine.medical_specialtyEndotheliumVasopressinsIndomethacinThyroid GlandProstacyclinIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyNitric oxideSuperior thyroid arterychemistry.chemical_compoundmedicine.arteryInternal medicinemedicineHumansDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsAgedVasopressin receptoromega-N-MethylarginineDose-Response Relationship DrugbiologyChemistryThyroidArteriesGeneral MedicineMiddle AgedArginine VasopressinNitric oxide synthaseEndocrinologymedicine.anatomical_structureVasoconstrictionbiology.proteinFemalehormones hormone substitutes and hormone antagonistsmedicine.drugLife Sciences
researchProduct

High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.

2015

Naringin is considered the major causative ingredient of the inhibition of intestinal drug uptake by grapefruit juice. Moreover, it is contained in highly dosed nutraceuticals available on the market. A controlled, open, randomized, crossover study was performed in 10 healthy volunteers to investigate the effect of high-dose naringin on the bioavailability of talinolol, a substrate of intestinal organic anion-transporting polypeptide (OATP)-mediated uptake. Following 6-day supplementation with 3 capsules of 350 mg naringin daily, 100mg talinolol were administered orally with 3 capsules of the same dietary supplement (1050 mg naringin) on the seventh day. This test treatment was compared to …

AdultMalefood.ingredientAdrenergic beta-AntagonistsPharmaceutical ScienceOrganic Anion TransportersPharmacologyPolymorphism Single NucleotideDosage formGrapefruit juicePropanolamineschemistry.chemical_compoundFood-Drug InteractionsYoung AdultNutraceuticalfoodPharmacokineticsHumansNaringinDosage FormsCross-Over StudiesDose-Response Relationship DrugChemistryCrossover studyBioavailabilityDietary SupplementsFlavanonesFemaleTalinololCitrus paradisiEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Inhibition of neutral endopeptidase (NEP) facilitates neurogenic inflammation

2005

Neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE) are involved in neuropeptide degradation and may modulate neurogenic inflammation. We therefore explored the effect of specific blockers of NEP and ACE on the intensity of neurogenic inflammation. We investigated eight subjects on three occasions. Two pairs of microdialysis fibers equipped with intraluminal wires were inserted intracutaneously into the volar forearms and electrical stimuli were delivered via the intraluminal electrodes. The microdialysis fibers were perfused either with normal saline, phosphoramidon (NEP inhibitor), or captopril (ACE inhibitor). CGRP release was assessed in the microdialysis eluate via a sp…

AdultMalemedicine.medical_specialtyMicrodialysisCaptoprilTime FactorsCalcitonin Gene-Related PeptideMicrodialysisPeptidyl-Dipeptidase AImmunoenzyme Techniqueschemistry.chemical_compoundDevelopmental NeuroscienceInternal medicineLaser-Doppler FlowmetrymedicineHumansDrug InteractionsEnzyme InhibitorsSkinNerve Fibers UnmyelinatedNeurogenic inflammationbiologyPhosphoramidonGlycopeptidesCaptoprilAngiotensin-converting enzymeElectric StimulationVasodilationAllodyniaEndocrinologyNeurologychemistryHyperalgesiaACE inhibitorHyperalgesiabiology.proteinFemaleNeprilysinNeurogenic Inflammationmedicine.symptommedicine.drugExperimental Neurology
researchProduct

Relaxation induced by milrinone and rolipram in human penile arteries and veins

2002

Abstract We studied the relaxant effects of milrinone, an inhibitor of phosphodiesterase 3, and rolipram, an inhibitor of phosphodiesterase 4, on contracted human penile dorsal artery and deep dorsal vein. Vascular rings from 12 multi-organ donors were suspended in organ baths for isometric recording of tension. Both milrinone and rolipram inhibited (100%) the contraction induced by noradrenaline and shifted the relaxation–response curves to the cAMP forming agents prostaglandin E1 and forskolin to the left. The findings indicate that the cAMP pathway appears to be a main determinant of relaxation in human penile vessels.

AdultMalemedicine.medical_specialtyPhosphodiesterase InhibitorsPhosphodiesterase 3Penile arteryBiologyMuscle Smooth Vascularchemistry.chemical_compoundInternal medicinemedicineHumansDrug InteractionsChildProstaglandin E1RolipramPharmacologyForskolinDose-Response Relationship DrugColforsinMiddle AgedVasodilationEndocrinologymedicine.anatomical_structurechemistryCirculatory systemMilrinoneRolipramMilrinonePenisBlood vesselmedicine.drugEuropean Journal of Pharmacology
researchProduct

Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial

2010

Aims The predominance of small dense low-density lipoproteins (sdLDLs) has been associated with increased cardiovascular risk. The effect of ezetimibe on LDL subfraction distribution has not been fully elucidated. This study assessed by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL subfraction distribution. Methods and results A single-centre, randomized, parallel three-group open-label study was performed in 72 healthy men with a baseline LDL-cholesterol (LDL-C) concentration of 111 ± 30 mg/dL (2.9 ± 0.8 mmol/L). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24), or their combination ( n = …

AdultMalemedicine.medical_specialtySimvastatinRandomizationCombination therapyAdolescent10265 Clinic for Endocrinology and Diabetology610 Medicine & health2705 Cardiology and Cardiovascular Medicinelaw.inventionYoung AdultRandomized controlled trialEzetimibelawInternal medicinemedicineDistribution (pharmacology)HumansDrug Interactionsbiologybusiness.industryAnticholesteremic AgentsLipoprotein(a)Middle AgedEzetimibeLipoproteins LDLEndocrinologySimvastatinMultivariate Analysisbiology.proteinAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationElectrophoresis Polyacrylamide GelatherosclerosisCardiology and Cardiovascular MedicinebusinessBody mass indexmedicine.drug
researchProduct

Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.

2005

Background:  Several in vitro studies demonstrate that corticosteroids and long-acting β2 agonists may have a complementary and synergistic mode of action on the inflammatory processes in asthma. Methods:  Sputum was induced in 20 mild to moderate asthmatic patients and the induced sputum cells (ISC) were cultured with beclomethasone dipropionate (BDP) 10−7 M, salbutamol 10−8 M and formoterol 10−8 M either alone or in combination, BDP plus salbutamol and BDP plus formoterol, for 24 h. We measured the levels of growth macrophages-colony stimulating factor (GM-CSF), released on activation normal T cells expressed and activated (RANTES) and interleukin-8 (IL-8), in the supernatant of stimulate…

AdultMalemedicine.medical_specialtymedicine.drug_classReceptor expressionImmunologySeverity of Illness IndexGlucocorticoid receptorReceptors GlucocorticoidInternal medicineFormoterol FumaratemedicineImmunology and AllergyHumansAlbuterolDrug InteractionsTissue DistributionAnti-Asthmatic AgentsChemokine CCL5Cells Culturedbusiness.industryInterleukin-8BeclomethasoneSputumGranulocyte-Macrophage Colony-Stimulating FactorBeclometasone dipropionaterespiratory systemMiddle AgedAsthmarespiratory tract diseasesBronchodilator AgentsEndocrinologyEthanolaminesSalbutamolCorticosteroidFormoterol FumarateDrug Therapy CombinationFemaleFormoterolReceptors Adrenergic beta-2businessEx vivomedicine.drugAllergy
researchProduct